Integra LifeSciences Holdings Corporation has entered into an amendment to its existing corporate loan agreement, originally established on March 24, 2023. The amendment, dated June 6, 2025, involves a syndicate of lending banks including Bank of America, Citibank, JPMorgan Chase, and others. While the amendment does not increase Integra's total indebtedness, it introduces temporary changes during a Covenant Relief Period. These changes include a revised applicable rate schedule and restrictions on certain investments, incremental indebtedness, and transactions involving intellectual property. The amendment aims to provide Integra with financial flexibility while maintaining compliance with its existing credit arrangements.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.